This post was originally published on this site Susan G. Komen, the Inflammatory Breast Cancer (IBC) Research Foundation, and the Milburn Foundation have joined to raise more than $850,000 for research targeting innovative diagnostic tools and therapy options, and to address questions and challenges in inflammatory breast cancer. Inflammatory breast cancer is a rare but…
This post was originally published on this site Dendreon Pharmaceuticals has completed patient enrollment ahead of schedule in an ongoing Phase 3 trial assessing the safety and efficacy of its immunotherapy Provenge (sipuleucel-T) for men with early-stage prostate cancer on active surveillance, the company announced. The open-label ProVent trial (NCT03686683) included more than 450 participants…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted fast track designation to Triumvira Immunulogics‘ investigational T-cell therapy TAC01-CD19 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The designation facilitates the development and review process of therapies that can treat severe conditions and…
This post was originally published on this site Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly…
This post was originally published on this site A Phase 1 clinical trial testing DRGT-45 — a new oral formulation of abiraterone acetate — in men with prostate cancer has dosed its first participant, the treatment’s developer, Druggability Technologies (DRGT), announced. Abiraterone acetate is a form of hormone therapy already approved for men with advanced,…
This post was originally published on this site A combination of Opdivo (nivolumab) and Avastin (bevacizumab) is safe and has strong clinical activity in women with relapsed ovarian cancer, especially among those whose tumors were sensitive to platinum-based chemotherapy, a Phase 2 clinical trial shows. The study, “Assessment of Combined Nivolumab and Bevacizumab in Relapsed…
This post was originally published on this site A new approach using genetically modified T-cells — via CRISPR-Cas9 gene editing technology — safely and effectively targets cancer cells in patients with advanced multiple myeloma, preliminary data from a U.S.-based Phase 1 study show. Despite their preliminary nature, researchers believe these findings raise hope that this…
This post was originally published on this site CytomX Therapeutics has initiated a Phase 2 clinical trial to test a combination of its probody CX-072 — a type of engineered antibody — with Yervoy (ipilimumab) for treating people with relapsed or refractory melanoma. The investigational probody CX-072 and Yervoy, developed by Bristol-Myers Squibb, are two…
This post was originally published on this site For patients with gene mutations that increase their risk for diseases such as breast cancer, fertility and in vitro fertilization (IVF) center Shady Grove Fertility (SGF) is offering individualized testing to lower the risk of passing the mutation to their children. To educate patients about such interventions, as…
This post was originally published on this site Commonly used in primary healthcare, blood tests for CA125 may help diagnose ovarian cancer and other types of cancer, particularly in older individuals, new research suggests. The findings were described in two presentations at the recent 2019 National Cancer Research Institute (NCRI) Conference in Glasgow, UK. The…
